Latvian-born scientist and CEO at the forefront of AI-driven biotech
Investors have pushed new biotech winners — from Novo Nordisk’s semaglutide pill to startups tackling baldness and targeted autoimmune drugs — while market enthusiasm has cooled for some forecasts. Novo Nordisk has released a daily weight‑loss pill used by over 1.5 million people; hair‑loss startups have sent small caps soaring; India’s low‑cost GLP‑1 generics have underperformed expectations.